Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119 AM2)

This study has been terminated.
(In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a significant increase in incidence of some types of non-fatal SAEs)
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01228019
First received: October 22, 2010
Last updated: May 23, 2013
Last verified: May 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2013
  Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)